Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by VALNEVA
< Previous
1
2
Next >
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada
September 18, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces the Success of its Private Placement Raising approximately €60 Million
September 13, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
September 03, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
August 13, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
August 01, 2024
From
VALNEVA
Via
GlobeNewswire
CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine
July 22, 2024
From
VALNEVA
Via
GlobeNewswire
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion
July 17, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®
July 01, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
June 26, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®
June 24, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
June 05, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
June 04, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
June 03, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
May 31, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
May 21, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
May 13, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 07, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
March 26, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
March 25, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.
March 21, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
March 20, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed
March 18, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
March 04, 2024
From
VALNEVA
Via
GlobeNewswire
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
February 29, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
February 15, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Announces Sale of Priority Review Voucher for $103 Million
February 05, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
January 10, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
January 04, 2024
From
VALNEVA
Via
GlobeNewswire
Valneva Provides Updated 2023 Financial Guidance
December 29, 2023
From
VALNEVA
Via
GlobeNewswire
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of Directors
December 20, 2023
From
VALNEVA
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.